The synergistic antileukemic effects of eltrombopag and decitabine in myeloid leukemia cells

BACKGROUND: Hypomethylating agents (HMAs), such as decitabine (DAC), are currently used as first-line therapy for patients with high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) not eligible for standard chemotherapies. Exacerbation of thrombocytopenia is one of the prev...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Manag Res
Main Authors: Shi, Mingyue, Xu, Fangfang, Yang, Xiawan, Bai, Yanliang, Niu, Junwei, Drokow, Emmanuel Kwateng, Chen, Mingyi, Chen, Yuqing, Sun, Kai
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735651/
https://ncbi.nlm.nih.gov/pubmed/31564981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S213931
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados